These results indicated that MAGEA3 is a novel biomarker and correlated with lymph node metastasis and immune infiltrates in GC, which could be a new target for immunotherapy. This evidence concerns the gene MAGEA3 and metastatic malignant neoplasm in the lymph nodes.